The estimated Net Worth of Francois Lebel is at least $3.77 Million dollars as of 21 June 2022. Francois Lebel owns over 12,763 units of Spectrum Pharmaceuticals stock worth over $664,134 and over the last 9 years he sold SPPI stock worth over $435,068. In addition, he makes $2,666,770 as Executive Vice President and Chief Medical Officer at Spectrum Pharmaceuticals.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Francois Lebel SPPI stock SEC Form 4 insiders trading
Francois has made over 13 trades of the Spectrum Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 12,763 units of SPPI stock worth $10,466 on 21 June 2022.
The largest trade he's ever made was selling 50,235 units of Spectrum Pharmaceuticals stock on 15 March 2022 worth over $35,667. On average, Francois trades about 12,112 units every 128 days since 2015. As of 21 June 2022 he still owns at least 644,790 units of Spectrum Pharmaceuticals stock.
You can see the complete history of Francois Lebel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Francois Lebel biography
Dr. Francois J. Lebel M.D. serves as Executive Vice President, Chief Medical Officer of the Company. Dr. Lebel has served as our Executive Vice President and Chief Medical Officer since November 2018. Prior to joining Spectrum, he provided strategic leadership on eight NDA/BLAs in various therapeutic areas and on several mergers and acquisitions. Dr. Lebel has broad and deep experience in oncology drug development, medical affairs, regulatory and pharmacovigilance acquired through various roles of increasing responsibilities at Chiron (Novartis), Warner-Lambert (Pfizer) and Burroughs Wellcome (GSK). From March 2013 to October 2018, he served as Executive Vice President, Research and Development, Chief Medical Officer at ZIOPHARM Oncology. He also held various leadership roles including Vice President of Research and Development at Baxter International and Global Head of Medical and Scientific Affairs at MedImmune. Dr. Lebel brings nearly 30 years of clinical leadership experience within the biopharmaceutical industry. He has designed and managed global medical organizations to deliver results, enhance productivity and practice sound risk management.
What is the salary of Francois Lebel?
As the Executive Vice President and Chief Medical Officer of Spectrum Pharmaceuticals, the total compensation of Francois Lebel at Spectrum Pharmaceuticals is $2,666,770. There are 4 executives at Spectrum Pharmaceuticals getting paid more, with Joseph Turgeon having the highest compensation of $5,697,230.
How old is Francois Lebel?
Francois Lebel is 68, he's been the Executive Vice President and Chief Medical Officer of Spectrum Pharmaceuticals since 2018. There are 3 older and 11 younger executives at Spectrum Pharmaceuticals. The oldest executive at Spectrum Pharmaceuticals, Inc. is Dolatrai Vyas, 76, who is the Independent Director.
What's Francois Lebel's mailing address?
Francois's mailing address filed with the SEC is 11500 S. EASTERN AVE., SUITE 220, , HENDERSON, NV, 89052.
Insiders trading at Spectrum Pharmaceuticals
Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen, and Thomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.
What does Spectrum Pharmaceuticals do?
spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.
What does Spectrum Pharmaceuticals's logo look like?
Complete history of Francois Lebel stock trades at Spectrum Pharmaceuticals and Alaunos Therapeutics Inc
Spectrum Pharmaceuticals executives and stock owners
Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Joseph Turgeon,
President, Chief Executive Officer, Director -
Thomas Riga,
Chief Operating Officer, Chief Commercial Officer, Executive Vice President -
Kurt Gustafson,
Chief Financial Officer, Executive Vice President -
Keith McGahan,
Senior Vice President, Chief Legal Officer, Corporate Secretary -
Francois Lebel,
Executive Vice President, Chief Medical Officer -
Thomas J. Riga,
Pres, CEO & Director -
Kurt A. Gustafson,
Exec. VP & CFO -
Dr. Francois J. Lebel FRCPC, M.D.,
Exec. VP & Chief Medical Officer -
Keith M. McGahan J.D., L.L.M.,
Exec. VP, Chief Legal Officer & Corp. Sec. -
William Ashton,
Independent Chairman of the Board -
Bernice Welles,
Independent Director -
Jeffrey Vacirca,
Independent Director -
Dolatrai Vyas,
Independent Director -
Elizabeth Czerepak,
Independent Director -
Seth Fischer,
Independent Director -
Lyndah Dreiling,
Senior Vice President, Clinical Development -
Dr. Lyndah K. Dreiling M.B.A., M.D.,
Sr. VP of Clinical Devel. -
Lisa A. Croissant,
VP of Sales -
Alberto Dejesus,
VP of Marketing -
Bimal R. Shah,
VP of Corp. & Bus. Devel. -
Anthony E Iii Maida,
Director -
Raymond W Cohen,
Director -
Stuart Mitchell Krassner,
Director -
Gilles Gagnon,
Director -
Luigi Md Lenaz,
President, Oncology Division -
Juhyun Lim,
Director -
Jeff L Vacirca,
Director -
Ann C Phd Kessler,
Director -
Armin M Kessler,
Director -
Lee F Md Ph D Allen,
Chief Medical Officer -
Joseph Kenneth Keller,
EVP & Chief Operating Officer -
Carol Phd Ocleireacain,
Director -
Paul H Phd Silverman,
Director -
Shyam K Kumaria,
Vice President Finance -
Mark J Glasky,
Director -
Krishan K Arora,
Director -
Eric L Phd Nelson,
Director -
John L Mcmanus,
VP,Finance, Strategic Planning -
Rajesh C Md Shrotriya,
Ch, Pres. and Chief Exec. Off. -
Julius A Vida,
Director -
Dilip J Md Phd Mehta,
Director -
Richard Fulmer,
Director -
James Shields,
Chief Commercial Officer -
Brett L Scott,
Acting Chief Financial Officer -
Anton Gueth,
Director -
Mitchell P. Cybulski,
Director -
George F Tidmarsh,
CSO AND HEAD OF R&D OPERATIONS -
Nora Brennan,
See Remarks